GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Quanterix Corp (NAS:QTRX) » Definitions » Debt-to-EBITDA

Quanterix (Quanterix) Debt-to-EBITDA : -0.88 (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Quanterix Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Quanterix's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $4.2 Mil. Quanterix's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $37.2 Mil. Quanterix's annualized EBITDA for the quarter that ended in Dec. 2023 was $-47.2 Mil. Quanterix's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.88.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Quanterix's Debt-to-EBITDA or its related term are showing as below:

QTRX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.13   Med: -0.48   Max: -0.2
Current: -1.04

During the past 9 years, the highest Debt-to-EBITDA Ratio of Quanterix was -0.20. The lowest was -1.13. And the median was -0.48.

QTRX's Debt-to-EBITDA is ranked worse than
100% of 429 companies
in the Medical Devices & Instruments industry
Industry Median: 1.24 vs QTRX: -1.04

Quanterix Debt-to-EBITDA Historical Data

The historical data trend for Quanterix's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quanterix Debt-to-EBITDA Chart

Quanterix Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only -0.20 -1.13 -0.41 -0.67 -1.04

Quanterix Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.00 -1.38 -1.52 -0.83 -0.88

Competitive Comparison of Quanterix's Debt-to-EBITDA

For the Medical Devices subindustry, Quanterix's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Quanterix's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Quanterix's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Quanterix's Debt-to-EBITDA falls into.



Quanterix Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Quanterix's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(4.241 + 37.223) / -39.785
=-1.04

Quanterix's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(4.241 + 37.223) / -47.156
=-0.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Quanterix  (NAS:QTRX) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Quanterix Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Quanterix's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Quanterix (Quanterix) Business Description

Traded in Other Exchanges
N/A
Address
900 Middlesex Turnpike, Billerica, MA, USA, 01821
Quanterix Corp is a life sciences company. It focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum and other fluids which are undetectable using conventional, analog immunoassay technologies. The company has developed Simoa technology which is a method of detection of proteins and has the capability of analyzing nearly six biomarkers per test, with anticipated expansion capability.
Executives
Laurie J Olson director C/O PFIZER INC. CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
William P Donnelly director C/O INGERSOLL RAND INC., 525 HARBOUR PLACE DRIVE, SUITE 600, DAVIDSON NC 28036
Vandana Sriram officer: Chief Financial Officer 15 ELIZABETH DRIVE, CHELMSFORD MA 01824
Brian J Blaser director 561 CIRCLE LANE, LAKE FOREST IL 60045
Michael A Doyle officer: CFO and Treasurer C/O EASYLINK SERVICES CORPORATION, 33 KNIGHTSBRIDGE ROAD, PISCATAWAY NJ 08854
Masoud Toloue officer: President, Quanterix & Dx C/O QUANTERIX CORP, 900 MIDDLESEX TURNPIKE, BILLERICA MA 01821
Sarah E. Hlavinka director 2111 N MOLTER RD, LIBERTY LAKE WA 99019
Paul M Meister director 18 SHIP ROCK ROAD, NORTH HAMPTON NH 03862
David R Walt director 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Martin D Madaus director 290 CONCORD ROAD, BILLERICA MA 01821
John J Fry officer: General Counsel & Secretary 8 CENTENNIAL DRIVE, PEABODY MA 01960
E Kevin Hrusovsky director, officer: EC, President & CEO 68 ELM STREET, HOPKINTON MA 01748
Karen Flynn director C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
David C. Duffy officer: SVP R&D and CTO C/O QUANTERIX CORPORATION, 113 HARTWELL AVENUELE, LEXINGTON MA 02421
Dawn Mattoon officer: Sr VP, Stgc Mrktg & Assay Tech 113 HARTWELL AVENUE, C/O QUANTERIX CORPORATION, LEXINGTON MA 02421